GLSINasdaqPharmaceutical PreparationsFiscal year ends December 31

Greenwich LifeSciences, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026

$15.21+0.66 (+4.54%)

Close on Oct 19, 2026

Market cap: $222.39M
P/E (TTM): –
Dividend yield: –

Greenwich LifeSciences, Inc. balance sheet

Annual Quarterly

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31
Cash & Equivalents	6.18	4.09	6.99	13	27	29	0.01	–
Cash & Short-Term Investments	6.18	4.09	6.99	13	27	29	0.01	–
Total Current Assets	6.18	4.09	–	–	–	29	0.01	–
Intangible Assets	–	0.00	0.01	0.01	0.01	0.02	0.02	–
Total Assets	6.18	4.09	6.99	13	27	29	0.03	–
Accounts Payable	4.65	2.80	0.26	0.22	0.22	0.71	0.73	–
Total Current Liabilities	5.82	3.19	0.29	0.26	0.39	1.05	1.38	–
Total Liabilities	5.82	3.19	0.29	0.26	0.39	1.05	1.38	–
Common Stock	0.01	0.01	0.01	0.01	0.01	0.01	0.01	–
Additional Paid-In Capital	87	69	57	55	60	57	26	–
Retained Earnings	-87	-68	-50	-41	-34	-29	-27	–
Shareholders' Equity	0.35	0.91	6.70	13	27	28	-1.35	-10
Total Equity	0.35	0.91	6.70	13	27	28	-1.35	-10
Total Liabilities & Equity	6.18	4.09	6.99	13	27	29	0.03	–
Shares Outstanding(shares)	14	13	13	13	13	13	8.46	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -3068.2%

Financial strength

Current ratio: 1.54
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 154.1%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 71.35
Dividend yield: –